ADVM Insider Trading

Insider Ownership Percentage: 4.20%
Insider Buying (Last 12 Months): $1,663,951.50
Insider Selling (Last 12 Months): $0.00

Adverum Biotechnologies Insider Trading History Chart

This chart shows the insider buying and selling history at Adverum Biotechnologies by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$1M$0$1MTotal Insider BuyingTotal Insider Selling

Adverum Biotechnologies Share Price & Price History

Current Price: $4.00
Price Change: Price Decrease of -0.13 (-3.15%)
As of 02/19/2025 05:00 PM ET

This chart shows the closing price history over time for ADVM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MarAprMayJunJulAugSepOctNovDecJanFeb$4.14Closing price on 02/18/25:

SEC Filings (Institutional Ownership Changes) for Adverum Biotechnologies (NASDAQ:ADVM)

48.17% of Adverum Biotechnologies stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ADVM by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$2.71Mbought$893ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$40M-$20M$0$20M$40MTotal InflowsTotal Outflows
Adverum Biotechnologies logo
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with wet age-related macular degeneration and diabetic macular edema which is in phase 2 clinical trials. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Read More on Adverum Biotechnologies

Today's Range

Now: $4.00
Low: $3.97
High: $4.20

50 Day Range

MA: $4.61
Low: $4.03
High: $5.93

52 Week Range

Now: $4.00
Low: $3.85
High: $22.40

Volume

150,324 shs

Average Volume

163,148 shs

Market Capitalization

$83.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94

Who are the company insiders with the largest holdings of Adverum Biotechnologies?

Adverum Biotechnologies' top insider shareholders include:
  1. Braden Michael Leonard (Major Shareholder)
  2. Laurent Fischer (CEO)
  3. Peter Soparkar (COO)
  4. Brigit Riley (Insider)
  5. James Paul Scopa (Director)
  6. Setareh Seyedkazemi (Insider)
Learn More about top insider investors at Adverum Biotechnologies.

Who are the major institutional investors of Adverum Biotechnologies?

Adverum Biotechnologies' top institutional shareholders include:
  1. TCG Crossover Management LLC — 8.64%
  2. Geode Capital Management LLC — 2.13%
  3. Dimensional Fund Advisors LP — 1.50%
  4. Regeneron Pharmaceuticals Inc. — 0.87%
  5. Northern Trust Corp — 0.73%
  6. Renaissance Technologies LLC — 0.62%
Learn More about top institutional investors of Adverum Biotechnologies stock.

Which major investors are selling Adverum Biotechnologies stock?

Within the previous quarter, ADVM stock was sold by these institutional investors:
  1. TCG Crossover Management LLC
  2. Group One Trading LLC
  3. Hsbc Holdings PLC
  4. Northern Trust Corp

Which major investors are buying Adverum Biotechnologies stock?

During the last quarter, ADVM stock was acquired by institutional investors including:
  1. Regeneron Pharmaceuticals Inc.
  2. Dimensional Fund Advisors LP
  3. Renaissance Technologies LLC
  4. Trexquant Investment LP
  5. Marshall Wace LLP
  6. D. E. Shaw & Co. Inc.
  7. Grant GrossMendelsohn LLC
  8. Corton Capital Inc.
In the last year, these company insiders have bought Adverum Biotechnologies stock:
  1. Braden Michael Leonard (Major Shareholder)
  2. Laurent Fischer (CEO)
Learn More investors buying Adverum Biotechnologies stock.